Match Document Document Title
US20140242169 TAPENTADOL COMPOSITIONS  
The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol...
US20140072623 GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
US20110293539 FILM CONTAINING COMPOSITIONS  
An oral care, personal care or cleansing composition with a carrier comprising a functional material and at least two polymers. One polymer has a greater solubility in water than the other...
US20110171310 HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE  
The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.
US20110020312 METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS  
Methods and formulations for treating metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
US20100310482 3-Deoxyglucosone And Skin  
The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of...
US20100297229 TAPENTADOL COMPOSITIONS  
The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol...
US20100056632 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG  
A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.
US20090239949 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same  
Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a...
US20090076053 METHODS AND COMPOSITIONS FOR TREATING PAIN  
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux...
US20070053996 LIGHT-ACTIVATED CATION CHANNEL AND USES THEREOF  
The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for...
US20060111307 Methods and compositions for treating pain  
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux...
US20050261280 Stabilized antihistamine syrup  
An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, such as a salt of...
US20050163848 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin  
A complex comprised of gabapentin or pregabalin and a transport moiety, such as an alkyl sulfate, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly...
US20160175436 COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES  
In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any...
US20140200516 BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING METABOLIC DISORDERS  
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in...
US20090325949 5 HT RECEPTOR MEDIATED NEUROGENESIS  
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes...
US20080044482 ORALLY ADMINISTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT  
Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for...
US20070293570 PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS  
The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a...
US20050207983 Formulations decreasing particle exhalation  
Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial...
US20050143436 Inhibitors of interleukin-1beta converting enzyme  
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural...
US20130303618 Solid Pharmaceutical Compositions Containing Pregabalin  
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration....
US20130102675 Solid Pharmaceutical Compositions Containing Pregabalin  
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration....
US20120232149 SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN  
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration....
US20120029081 Solid Pharmaceutical Compositions Containing Pregabalin  
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration....
US20110301100 Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons  
A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5%...
US20080318932 Sodium Channel Blocker Compositions and the Use Thereof  
Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are...
US20080031833 Combined energy and topical composition application for regulating the condition of mammalian skin  
Method for regulating the condition of mammalian skin comprising the steps of applying a first personal care composition to an area of skin where regulation is desired, wherein the first personal...
US20080009498 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use  
The invention provides novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous...
US20070276039 PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS  
The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a...
US20070112017 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS  
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes...
US20070092579 Medical Products and Parenteral Formulations  
A medical product and parenteral formulation are provided. The parenteral formulation is preferably for fluid restricted patients such as pediatric patients and can include amino acids, lipids,...
US20070087977 METHODS AND COMPOSITIONS FOR TREATING PAIN  
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux...
US20060029585 Methods for reducing morbidity  
Various compositions containing transfer factor in combination with nutraceuticals are provided including transfer factor in combination with zinc and essential fatty acids and transfer factor in...
US20050228049 Methods for decreasing detrusor  
A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit...
US20150157558 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
US20150031761 USE OF 5-AMINOLEVULINIC ACID AND DERIVATIVES IN A SOLID FORM FOR PHOTODYNAMIC TREATMENT AND DIAGNOSIS  
The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the...
US20100166889 METHOD OF TREATING DEPRESSIVE DISORDERS  
The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs,...
US20100166825 TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS  
Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of...
US20090306051 Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders  
The present invention relates to methods and compositions for treating CNS-related disorders.
US20090299268 Topical Aminolevulinic Acid-Photodynamic Therapy for the Treatment of Acne Vulgaris  
Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the...
US20090234009 Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof  
Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or...
US20090203792 METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS  
A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit...
US20090191282 CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT  
A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions...
US20080085916 METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS  
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth...
US20070213401 PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS  
The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a...
US20070203216 METHOD OF TREATING INFLAMMATORY DISEASES  
The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present...
US20060122271 Stable gabapentin having pH within a controlled range  
A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3.
US20050245460 Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders  
The present invention relates to methods and compositions for treating CNS-related disorders.
US20050239890 Methods for decreasing detrusor muscle overactivity  
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth...